Search Results

The SensiTox B. anthracis Toxin Test for use with the MultiPath Analyzer, is a qualitative immunofluorescence assay to aid in the diagnosis of inhalation anthrax. The test is intended for the rapid, qualitative detection of lethal factor, a biomarker associated with Bacillus anthracis). The test can be used with whole blood collected with dipotassium EDTA anticoagulant by venipuncture. This testing samples from individuals who have signs and symptoms consistent with inhalation anthrax and a likelihood of exposure to B. anthracis. A positive SensiTox B. anthracis Toxin Test result is presumptively diagnostic for B. anthracis infection. Diagnosis of B. anthracis infection must be made in conjunction with medical history, likelihood of exposure, signs, and symptoms of disease, as well as other laboratory evidence. The definitive identification of B. anthracis from blood samples additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required. Testing should be performed and reported in accordance with current guidelines provided by the appropriate public health authorities. The level of lethal factor present in blood from individuals with early systemic infection is unknown. Negative results do not preclude infection with the biothreat microbial agents targeted by the device and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Laboratories performing the SensiTox B. anthracis Toxin Test must have the appropriate biosafety equipment, personal protective equipment (PPE), containment facilities, and personnel trained in the safe handling of clinical specimens potentially containing B. anthracis. The SensiTox B. anthracis Toxin Test is for prescription use only. This assay is not FDA-cleared or approved for testing blood or plasma donors.

The SensiTox B. anthracis Toxin Test, run on the MultiPath Analyzer, detects lethal factor in venous whole blood samples using an immunofluorescence assay and the proprietary MultiPath detection technology. A whole blood specimen, collected in dipotassium EDTA, from individuals with signs and symptoms consistent with inhalation anthrax and a likelihood of exposure, is used for the test. The blood sample is added directly to the SensiTox B. anthracis Cartridge, a single use consumable that contains all the reagents required to run the test. The Cartridge is loaded onto the MultiPath Analyzer for processing through the steps of the assay. Once loaded onto the Analyzer, the barcodes on the cartridge that identify the test type and associated test specific information (manufacturer installed barcode) and sample (laboratory affixed barcode) are read. The cartridge is moved to the fluidics station where it is first heated to 35°C. The sample is then split into 3 equal aliquots in 3 distribution wells within the cartridge. The sample aliquots flow from the distribution wells to the reagent wells containing target-specific antibody conjugated fluorescent and magnetic particles in the form of lyophilized beads. Upon contact with the sample, the lyophilized beads rehydrate and the reaction mixtures flow into the imaging wells, the bottoms of which are coated with a dye cushion reagent. Upon contact with the reagents, the dye-cushion dissolves forming a dense opaque aqueous layer that separates the sample and reagents from the bottom optical surface of the Imaging Well. In the upper assay layer, the toxins, if present, bind to the magnetic and fluorescent particles tethering them together. The cartridge is incubated for 12 minutes to allow the reaction to take place and then is moved to the magnetics station. At the magnetics station, the imaging well is placed over permanent magnets that draw the magnetic particles and any fluorescent particles that are tethered to them via the target molecules through the dye-cushion layer, depositing them on the bottom imaging surface. The captured fluorescent particles are imaged and quantified using nonmagnified digital imaging. The Analyzer can be run in batch mode or by random access. Up to 20 cartridges can be loaded onto the Analyzer in parallel. The first result is reported in approximately 21 minutes of loading the cartridge onto the Analyzer with subsequent results being reported in 2.5-minute increments. The results are interpreted using the MultiPath applications software as valid or invalid, and if valid, the results are reported as Lethal Factor detected. Results are displayed on the instrument touch screen and can be printed.

The SensiTox C. difficile Toxin Test is an immunofluorescence assay intended for the qualitative detection of Clostridioides difficile toxins A and/or B in human stool specimens. The test is intended as an aid in the diagnosis of C. difficile infection (CDI) in patients exhibiting symptoms of CDI. Negative results do not preclude toxigenic C. difficile infection. The SensiTox C. difficile Toxin Test should not be used as the sole basis for treatment or other management decisions. The test can only be used with the MultiPath platform.

The SensiTox C. difficile Toxin Test detects toxins A and B in stool samples using an immunofluorescence assay and the proprietary MultiPath detection technology. The assay is performed on the proprietary MultiPath Analyzer. A stool sample is added to Stool Specimen Diluent, processed through a spin column, and the filtrate is added to the SensiTox C. difficile Cartridge. The Cartridge is loaded onto the MultiPath Analyzer for processing. The Analyzer reads barcodes, heats the cartridge, splits the sample into aliquots, mixes with antibody conjugated fluorescent and magnetic particles, and incubates. Magnetic particles and tethered fluorescent particles are drawn to the bottom imaging surface by magnets and imaged and quantified using non-magnified digital imaging. Results are interpreted by the MultiPath applications software.

Light Diagnostics SimulFluor® HSV1/2 Immunofluorescence Assay is a direct immunofluorescence test intended for the detection and identification of herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) following amplification in cell culture or by direct examination of clinical specimens prepared by cytocentrifugation. Specimens found to be negative on direct specimen examination should be tested by cell culture. For in vitro diagnostic use.

Light Diagnostics SimulFluor® HSV 1/2 Immunofluorescence Assay utilizes a single reagent for the simultaneous detection and identification of HSV-1 and HSV-2. The SimulFluor® HSV 1/2 Reagent consists of two components; the primary component specific for HSV-1 will bind to the glycoprotein C and a capsid-associated protein in HSV-1 infected cells, while the secondary component, specific for HSV-2, will bind to the glycoprotein G in HSV-2 infected cells. Unbound reagent is removed by rinsing with phosphate-buffered saline (PBS). Illumination with ultraviolet light allows visualization of the antigenantibody complexes by fluorescence microscopy. When an FITC filter set is used, HSV-1- infected cells will exhibit apple-green fluorescence and HSV-2infected cells will exhibit yellow-gold fluorescence. The uninfected cells will stain a dull red due to the presence of Evans blue in the SimulFluor® HSV 1/2 reagent. A blend of monoclonal antibodies directed against HSV-1 and HSV-2 is used in the Light Diagnostics SimulFluor® HSV 1/2 reagent. The use of monoclonal antibodies ensures increased specificity of reagent and reduces the risk of nonspecific background or interference.

Light Diagnostics SimulFluor™ HSV/VZV Immunofluorescence Assay is a direct immunofluorescence test intended for the simultaneous detection and identification of HSV 1 and 2 and varicella-zoster virus (VZV) from patients with vesicular, oral, genital, or skin lesions, and following amplification of virus in culture. Specimens found to be negative on direct specimen examination should be tested by cell culture.

Light Diagnostics SimulFluor™ HSV/VZV Immunofluorescence Assay utilizes a single reagent for the simultaneous detection and identification of HSV and VZV. The primary component, specific for both HSV 1 and 2 will bind to 155kD major capsid protein in HSV-infected cells. The secondary component, specific for VZV, will bind to glycoprotein gp I and the immediate early antigen in VZV-infected cells. Unbound reagent is removed by rinsing with phosphate-buffered saline (PBS). Illumination with ultraviolet light allows visualization of the antigen-antibody complexes by fluorescence microscopy. When a FITC filter set is used, the HSV antigen-antibody complex will exhibit an apple green fluorescence and the VZV antigen-antibody complex will fluoresce yellow-gold. Uninfected cells stain a dull red due to the presence of Evans blue in the reagent. A blend of monoclonal antibodies directed against HSV and VZV is used in the Light Diagnostics SimulFluor™ HSV/VZV reagent. The use of monoclonal antibodies ensures increased specificity of the reagent and reduces the risk of non-specific background or interference.

The Light Diagnostics Rabies DFA Reagent is intended for the detection of rabies antigens in culture and in acetone-fixed brain and submaxillary tissues of infected animals. Thus the assay could be used as an aid in the indirect diagnosis of human rabies virus infection. All specimens that are negative or indeterminate by DFA testing should be further tested by cell culture or animal inoculation methods.

Light Diagnostics Rabies DFA Reagent uses fluorescein-labeled monoclonal antibodies directed against the rabies nucleocapsid protein to detect the virus in infected tissue. The direct immunofluorescence assay requires incubation of a user-determined dilution of the reagent with suspected rabies-infected tissue such as brain (medulla, cerebellum, and hippocampus) and submaxillary salivary glands. If virus is present, the FITC-labeled monoclonal antibodies will bind to the nucleocapsid protein. Unbound antibody is removed by washing. The antigen-antibody complex is visualized using fluorescence microscopy. Positive reactions in infected tissue will appear as bright apple-green cytoplasmic inclusions or "dusting". A blend of monoclonal antibodies are used in the Light Diagnostics Rabies DFA reagent. These monoclonal antibodies are specific for the rabies virus nucleocapsid protein. The use of monoclonal antibodies ensures increased specificity of the reagent and reduces the risk of non-specific background or interference.

The Light Diagnostics SimulFluor™ Flu A/Flu B Immunofluorescence Assay is intended for the detection and identification of influenza A and influenza B in respiratory specimens such as throat, nasal and nasopharyngeal swabs, nasopharyngeal aspirates, broncho-alveolar lavages from patients with febrile respiratory illness and following amplification of virus in cell culture. Specimens found to be negative on direct specimen examination must be confirmed with culture. For in vitro diagnostic use.

Light Diagnostics SimulFluor™ Flu A/Flu B Immunofluorescence Assay utilizes a single reagent for the simultaneous detection and identification of influenza A and influenza B. The primary component, specific for influenza A, will bind to influenza A nucleoprotein in influenza A-infected cells. The secondary component, specific for influenza B, will bind to influenza B nucleoprotein in influenza B-infected cells. Unbound reagent is removed by rinsing with phosphate-buffered saline (PBS). The complexes are visualized with a fluorescence microscope. The influenza A antigenantibody complex will exhibit an apple-green fluorescence and the influenza B antigenantibody complex will be yellow-gold. Uninfected cells stain a dull red due to the presence of Evans blue in the reagent. antibodies ensures increased specificity of the reagent and reduces the risk of non-specific background or interference.

The Light Diagnostics Cytomegalovirus Direct Immunofluorescence Assay is intended for use in centrifugation enhanced shell vials in the qualitative detection and identification of immediate early antigen- of human CMV.

Light Diagnostics Cytomegalovirus Direct Immunofluorescence Assay (CMV DFA) uses the standard laboratory direct immunofluorescence technique for the culture confirmation of cytomegalovirus. The DFA is based on the principle of antigen identification using a detector monoclonal antibody conjugated to fluorescein isothiocyanate. The substrate consists of a slide prepared from the tissue cultured cells from a clinical specimen inoculum. Anti CMV FITC laheled antibody is applied to the substrate. The antibody will bind to specific antigen, if present, in the substrate. The fluorescein conjugated monoclonal antibody allows for visualization of the antigen / antibody complex by flucrescence microscopy. Mouse monoclonal antibody is used as the detector antibody in Light Diagnostics Cytomegalovirus Direct Immunofluorescence Assay. The use of monoclonal antibody ensures increased specificity and reduced non-specific interference. The monoclonal antibody is specific for a 68-72 kDa non-structural protein designated as immediate early (IE) antigen of human CMV.

Light Diagnostics Varicella-zoster virus Direct Immunofluorescence Assay is intended for in vitro diagnostic use in the qualitative detection of VZV from vesicular smears and in cell culture viral isolation and confirmation.

Light Diagnostics Varicella-zoster virus direct Immunofluorescence DFA) uses the standard laboratory direct Assav (VZV immunofluorescence technique for the culture confirmation and direct specimen detection of Varicella-zoster virus. The DFA is based on the principle of antigen identification using a detector monoclonal antibody conjugated to fluorescein isothiocyanate. The substrate consists of a slide prepared from a direct specimen vesicular smear or the tissue cultured cells from a clinical specimen inoculum. Anti VZV FITC labeled antibody is applied to the substrate. The antibody will bind to specific antigen, if present, in the substrate. The fluorescein conjugated monoclonal antibody allows for visualization of the antigen / antibody complex by fluorescence microscopy. A blend of mouse monoclonal antibodies are used as detector antibodies in Light Diagnostics Varicella-zoster virus direct Immunofluorescence Assay. The monoclonal antibodies are specific for the glycoprotein gp I or the immediate early antigen of VZV. The use of monoclonal antibodies ensures increased specificity and reduced non-specific interference.